Rilzabrutinib
EFC17093
Phase 3 small_molecule active
Quick answer
Rilzabrutinib for Immune Thrombocytopenia is a Phase 3 program (small_molecule) at Principia Biopharma, a Sanofi Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Principia Biopharma, a Sanofi Company
- Indication
- Immune Thrombocytopenia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active